Insight to Pharmacokinetics of TKIs: Optimizing Practical Guidelines for Individualized Therapy

Author(s): Ruiqing Wang, Chaoqin Zhong, Chen Zhang, Mingqiang Hua, Daoxin Ma

Journal Name: Current Drug Metabolism

Volume 18 , Issue 3 , 2017

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Objective: Tyrosine kinase inhibitors (TKIs) are widely used drugs which have high availability in reducing the activity of BCR-ABL1 tyrosine kinase, therefore they play an indispensable role in the treatment of Chronic myeloid leukemia (CML). Imatinib, dasatinib and nilotinib have been proved to have absolute bioavailability and stable blood concentration in humans. TKIs pharmacokinetics has close relationships with the clinical response and clinical treatment of CML.

Method: We conducted a systematic PubMed search to look for studies relating to TKIs pharmacokinetics with proper inclusion/exclusion criteria. After looking through a large number of references, we investigated that different generations of TKIs could be influenced by many factors. We chose some typical factors which were closely linked to the common treatment of CML. These factors contain daily dose, diet, individual variability, drug-drug interaction, drugs resistance and drug withdrawal.

Results: By summarizing up these influence factors, we hope it can make a contribution to clinical therapy. Above all, the relationship between influence factors and the clinical therapeutic effect is the key point that our research pays attention to.

Conclusion: This review highlights certain influence factors of TKIs clinical pharmacokinetics.

Keywords: Tyrosine kinase inhibitors (TKIs), chronic myeloid leukemia (CML), pharmacokinetics, influence factors, treatment, plasma concentration.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Published on: 30 March, 2017
Page: [199 - 206]
Pages: 8
DOI: 10.2174/1389200218666170116113705
Price: $65

Article Metrics

PDF: 82
PRC: 2